1
|
Passam F, Alexandrakis M, Moschandrea J, Sfiridaki A, Roussou P, Siafakas N. Angiogenic Molecules in Hodgkin's Disease: Results from Sequential Serum Analysis. Int J Immunopathol Pharmacol 2018. [DOI: 10.1177/205873920601900116] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Increased angiogenic activity has been demonstrated in lymphoproliferative diseases including Hodgkin's disease. In the current study, the levels of circulating angiogenic molecules in 60 Hodgkin's patients were determined prior to and after treatment and correlated to disease stage and prognostic score. Hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were increased in Hodgkin's patients in comparison to healthy controls (p<0.001). Angiogenin and angiopoietin-2 levels did not differ from controls. HGF, VEGF, TNF-α and angiogenin decreased significantly in Hodgkin's patients after standard treatment (p<0.001 for HGF, p<0.05 for VEGF, TNF-α and angiogenin). Furthermore, HGF and TNF-α increased with advancing stage of disease (p<0.05). HGF and VEGF correlated significantly with IL-6 (r=0.56, p<0.0005 and r=0.57, p<0.001 respectively). In conclusion, Hodgkin's disease displays an angiogenic activity as depicted by the increased serum levels of a number of angiogenic cytokines. HGF seems to be the prominent molecule in Hodgkin's disease, which may be used to monitor the disease status and the response to treatment.
Collapse
Affiliation(s)
- F.H. Passam
- III Dept of Internal Medicine, Sotiria Hospital, Medical School of Athens, University of Athens
| | | | - J. Moschandrea
- Dept of Social Medicine, Medical School of Crete, University of Crete
| | - A. Sfiridaki
- Dept of Hematology, Venizelion General Hospital, Heraklion, Crete, Greece
| | - P.A. Roussou
- III Dept of Internal Medicine, Sotiria Hospital, Medical School of Athens, University of Athens
| | - N.M. Siafakas
- Thoracic Medicine, University Hospital of Heraklion, Crete
| |
Collapse
|
2
|
Soliman AH. Diagnostic and Prognostic Relevance of Bone Marrow Microenvironment Components in Non Hodgkin’s Lymphoma Cases Before and After Therapy. Asian Pac J Cancer Prev 2016; 17:5273-5280. [PMID: 28125873 PMCID: PMC5454670 DOI: 10.22034/apjcp.2016.17.12.5273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Objective: To evaluate stromal cells of the bone marrow microenvironment (BMM) in bone marrow trephine biopsy (BMTB) specimens, with a focus on fibronectin, tumor necrosis factor- alpha (TNF-α) and L-selectin in Non-Hodgkin’s lymphoma (NHL) patients, before and after therapy. Materials and Methods: A total of 80 de novo NHL patients, 64 with B-cell lymphomas 80%, (follicular cell lymphoma (FCL) in 32, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in 12, and diffuse large cell lymphoma in 20) and 16 with T-cell lymphomas (20%) all diagnosed as T-Lymphoblastic lymphomas, were evaluated before and after therapy. For comparison, 25 age and sex matched BM donors, were included as a control group. BMTB material and BM aspirates were taken for morphological assessment of stromal cells, the plasma of these samples being examined for TNFα and L-selectin by ELISA, and fibronectin by radial immunodiffusion (RID). Results: BM stromal cells comprising reticular macrophages and fibroblasts were elevated in 53.3% of NHL cases at diagnosis, while BM fibronectin levels were decreased and BM TNFα and L-selectin were higher than in controls (p<0.05). In NHL cases, elevated values of BM TNFα and BM L-selectin were associated with signs of aggressive disease, including >1 extra nodal sites, detectable B symptoms, high grade, BM and CNS invasion, and a high International prognostic index (IPI) (p<0.05). Conclusion: BMM components, TNFα, L-selectin and fibronectin, in NHL can be useful in evaluating disease activity, extent and response to treatment and as prognostic markers according to the IPI.
Collapse
Affiliation(s)
- Amira H Soliman
- Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
| |
Collapse
|
3
|
Nakayama S, Yokote T, Tsuji M, Akioka T, Miyoshi T, Hirata Y, Hiraoka N, Iwaki K, Takayama A, Nishiwaki U, Masuda Y, Hanafusa T. Expression of tumour necrosis factor-α and its receptors in Hodgkin lymphoma. Br J Haematol 2014; 167:574-7. [DOI: 10.1111/bjh.13015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Shoko Nakayama
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Taiji Yokote
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Motomu Tsuji
- Department of Pathology; Osaka Medical College; Osaka Japan
| | - Toshikazu Akioka
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Takuji Miyoshi
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Yuji Hirata
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Nobuya Hiraoka
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Kazuki Iwaki
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Ayami Takayama
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Uta Nishiwaki
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Yuki Masuda
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| | - Toshiaki Hanafusa
- Department of Internal Medicine (I); Osaka Medical College; Osaka Japan
| |
Collapse
|
4
|
Tack GJ, van Wanrooij RLJ, Von Blomberg BME, Amini H, Coupe VMH, Bonnet P, Mulder CJJ, Schreurs MWJ. Serum parameters in the spectrum of coeliac disease: beyond standard antibody testing--a cohort study. BMC Gastroenterol 2012; 12:159. [PMID: 23145841 PMCID: PMC3579729 DOI: 10.1186/1471-230x-12-159] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2012] [Accepted: 11/04/2012] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Invasive techniques are still required to distinguish between uncomplicated and complicated forms of CD. METHODS We set out to investigate the potential use of novel serum parameters, including IL-6, IL-8, IL-17, IL-22, sCD25, sCD27, granzyme-B, sMICA and sCTLA-4 in patients diagnosed with active CD, CD on a GFD, Refractory coeliac disease (RCD) type I and II, and enteropathy associated T-cell lymphoma (EATL). RESULTS In both active CD and RCDI-II elevated levels of the proinflammatory IL-8, IL-17 and sCD25 were observed. In addition, RCDII patients displayed higher serum levels of soluble granzyme-B and IL-6 in comparison to active CD patients. In contrast, no differences between RCDI and active CD or RCDII were observed. Furthermore, EATL patients displayed higher levels of IL-6 as compared to all other groups. CONCLUSIONS A series of novel serum parameters reveal distinctive immunological characteristics of RCDII and EATL in comparison to uncomplicated CD and RCDI.
Collapse
Affiliation(s)
- Greetje J Tack
- Department of Gastroenterology and Hepatology, VU University Medical Centre, PO Box 7057, Amsterdam 1007 MB, The Netherlands
| | - Roy L J van Wanrooij
- Department of Gastroenterology and Hepatology, VU University Medical Centre, PO Box 7057, Amsterdam 1007 MB, The Netherlands
| | | | - Hedayat Amini
- Department of Pathology, VU University Medical Centre, Amsterdam The Netherlands
| | - Veerle M H Coupe
- Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam The Netherlands
| | - Petra Bonnet
- Department of Pathology, VU University Medical Centre, Amsterdam The Netherlands
| | - Chris J J Mulder
- Department of Gastroenterology and Hepatology, VU University Medical Centre, PO Box 7057, Amsterdam 1007 MB, The Netherlands
| | - Marco W J Schreurs
- Department of Pathology, VU University Medical Centre, Amsterdam The Netherlands
- Department of Immunology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
| |
Collapse
|
5
|
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. Tumour Biol 2012; 33:1733-8. [DOI: 10.1007/s13277-012-0432-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Accepted: 05/28/2012] [Indexed: 11/25/2022] Open
|
6
|
Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, Löffler M, Jung W, Pfreundschuh M, Trümper L, Kube D. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res 2012; 18:3637-47. [PMID: 22573350 DOI: 10.1158/1078-0432.ccr-11-3299] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Peripheral T-cell non-Hodgkin lymphomas (T-NHL) represent a small but heterogeneous and clinically aggressive subset of NHLs with a poor outcome. Cytokines or their receptors might be associated with the clinical outcome of these lymphomas. Therefore, we tested whether gene variations and serum levels of soluble TNF receptor (TNFR)I (sTNFRI), sTNFRII, interleukin (IL)-10, or sIL-4R are predictive for treatment response in T-NHLs. EXPERIMENTAL DESIGN Peripheral blood DNA from 117 patients with T-NHL treated in prospective clinical trials was subjected to genotyping analysis. Whenever possible, pretreatment sera were obtained, and circulating levels of sTNFRI, sTNFRII, IL-10, and sIL-4R were determined with a specific capture enzyme-linked immunoassay. RESULTS Patients characterized by TNFRI-609GG (rs4149570) showed a trend toward better event free survival [EFS; univariate: P = 0.041; multivariate: HR, 1.76; confidence interval (CI), 0.99-3.14 with P = 0.056]. A protective role of IL-10-1087A, -824T, and -597A reported in another study was not confirmed in our cohort. Patients with circulating levels of soluble TNFRII ≥2.16 ng/mL had a 2.07-fold increased relative risk for shorter overall survival (OS; univariate: P = 0.0034; multivariate: HR, 2.07; CI, 0.92-4.70 with P = 0.081) and a 2.49-fold higher risk for shorter EFS (univariate: P = 0.00068; multivariate: HR, 2.49; CI, 1.22-5.08 with P = 0.012). Elevations of circulating levels of sTNFRI, IL-10, and sIL-4R are frequent, but the clinical response in these patients is not significantly different. CONCLUSIONS Our findings suggest a critical role for TNF-TNFR signaling for the clinical outcome of patients with peripheral T-NHLs.
Collapse
Affiliation(s)
- Christina Heemann
- Department of Hematology and Oncology, Medical Center of the Georg-August-University Göttingen, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006; 77:217-25. [PMID: 16856931 DOI: 10.1111/j.1600-0609.2006.00702.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Recently investigators have worked to identify prognostic factors in non-Hodgkin's lymphoma (NHL) so an appropriate therapeutic plan can be put in action. The aim of the present study was to assess the prognostic significance of serum soluble tumor necrosis factor receptor (sTNF-R) 2 in aggressive NHL. METHODS One hundred and ten consecutive patients with aggressive NHL who were previously untreated (diffuse large B-cell lymphoma; 94, peripheral T-cell lymphoma; 16) were prospectively enrolled in this study between 1997 and 2002. The patients were treated with 6-8 cycles of CHOP or THP-COP regimens. RESULTS High serum sTNF-Rs level was associated with some poor prognostic factors and low complete remission rate. Patients with high sTNF-R1 (4 ng/mL and over) and sTNF-R2 (15 ng/mL and over) at onset had significantly lower survival rates (5 yr: 19%, 19%) than those with low sTNF-R1 (under 4 ng/mL) and sTNF-R2 (under 15 ng/mL) (62% and 69%), respectively (P < 0.0005 and 0.0001). Multivariate analysis employing sTNF-R2 and some conventional prognostic factors demonstrated that a combination of sTNF-R2 and performance status, and that of sTNF-R2, sIL-2R, and LDH were significant prognostic factors for poor overall survival and for poor event-free survival, respectively. In addition, we attempted to use sTNF-R2 in combination with the international prognostic index (IPI). The patients in the high risk group and those with high sTNF-R2 in the low-intermediate (LI)/high-intermediate (HI) risk group had significantly lower survival rates than the patients in the low risk group and those with low sTNF-R2 in LI/HI risk group (P < 0.0001). CONCLUSIONS The results suggest that a high serum sTNF-R2 level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.
Collapse
Affiliation(s)
- Naoe Goto
- First Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Pedersen LM, Sørensen PG. Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma. Br J Haematol 2003; 121:275-9. [PMID: 12694249 DOI: 10.1046/j.1365-2141.2003.04285.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Recent studies have demonstrated a high frequency of minor glomerular leakage of albumin in cancer patients. Pathogenic mechanisms of increased urinary albumin excretion (UAE) in malignancies remain to be clarified. We have attempted to identify whether microalbuminuria in lymphoma patients is associated with inflammatory mediators and the acute-phase response. UAE, urinary excretion of beta2-microglobulin and IgG, and serum levels of interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-alpha) and C-reactive protein (CRP) were determined in 113 patients with newly diagnosed non-Hodgkin's lymphoma. We demonstrated a high frequency of microalbuminuria (>or= 20 microg/min) and UAE correlated strongly with serum levels of CRP, IL-6 and TNF-alpha. UAE, CRP, IL-6 and TNF-alpha were significantly higher in patients with advanced disease stage, B symptoms and in high-risk patients according to the International Prognostic Index. Urinary excretion of beta2-microglobulin was unaffected in patients with increased UAE. However, UAE was significantly correlated with urinary excretion of IgG, suggesting an altered size selectivity of the glomerular filtration barrier. This is the first study that shows a direct correlation between microalbuminuria and proinflammatory cytokines in malignancies, indicating a pathogenic relationship between inflammation and glomerular leakage of albumin. Future efforts should focus on the pathophysiological cause-effect mechanisms and larger studies are needed to confirm the clinical significance of UAE.
Collapse
Affiliation(s)
- Lars Møller Pedersen
- Department of Haematology, Herlev Hospital, University of Copenhagen, DK-Herlev, Denmark.
| | | |
Collapse
|
9
|
Bercovici JP, Machelon V, Gaudin-Nome F, Roudaut N, Conan-Charlet V, Leroy JP, Sensebe L, Kerlan V. Hodgkin's disease masquerading as fibrous thyroiditis: potential role of cytokines in in vivo and in vitro studies. Clin Endocrinol (Oxf) 2002; 57:691-7. [PMID: 12390346 DOI: 10.1046/j.1365-2265.2002.01648.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Hodgkin's disease appearing as, or associated with, fibrous thyroiditis has only been described rarely. We report the observation of a patient presenting with a goitre, fibrosis of the thyroid and adjacent structures, and hypothyroidism. The histological examination was compatible with fibrosclerotic thyroiditis. This diagnosis was reviewed 6 months later when the biopsy of a supraclavicular nodule that had subsequently appeared led to the diagnosis of a nodular-sclerosis type of Hodgkin's disease. The plasmatic levels of interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) were very high compared to the levels in healthy subjects (12 and 40 IU/l vs. 0.05 and 2.0 IU/l, respectively). These cytokine levels decreased when the initial illness was treated, and their normalization was associated with the disappearance of the cervical and thyroidal fibroses. A parallel in vitro study of these cytokines and of TNF-alpha receptors and IL-13 was performed. The results suggest a possible cause-and-effect relationship between IL-6 and IL-13 produced locally by the tumoral tissue and the development of cervical fibrosis.
Collapse
Affiliation(s)
- Jean Pierre Bercovici
- Départements d'Endocrinologie, d'Hématologie, et d'Anatomie pathologique, CHU Brest, Clamart, France
| | | | | | | | | | | | | | | |
Collapse
|